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DNase I hypersensitivity (DHS) combined with next gen-
eration sequencing (DNase-seq) is an efficient way of
observing, in a single experiment, the genome-wide chro-
matin effects associated with the binding of multiple tran-
scription factors. Using quantitative contrasts of DHS
before and after estrogen and androgen stimulation in
breast and prostate cancer cell lines, we have shown that
differential DHS can accurately predict hormone induced
transcription factor binding. Despite its effectiveness, the
DHS assay can vary significantly depending on the experi-
mental parameters. To increase the robustness of this
assay, we have systematically evaluated two major para-
meters, digestion level and fragment size. We found that
while there is a broad range of suitable digestion level,
over-digestion dramatically decreases the efficiency of
detecting DHS regions. More interestingly, we found that
different fragment sizes capture distinct chromatin ele-
ments, and thus represent different chromatin structures.
We were able to classify different combinations of estro-
gen receptor coregulators that resulted in different local
chromatin structures.
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